BioArctic’s partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day

Eisai published a simulation projecting Leqembi sales of around JPY 300 billion (about SEK 17.6 billion) in FY2028, ending March 2029. The update is supportive for BioArctic because it reinforces long-term commercial potential for the partnered Alzheimer’s therapy. The release is informational rather than a new financial result, so immediate market impact should be limited.

Analysis

The important signal is not the near-term number, but the implied trajectory of payer adoption and channel normalization into FY28. A credible multi-year sales simulation from the partner functionally lowers uncertainty around the launch curve, which can re-rate the asset base well before revenue is fully visible in reported numbers. For BioArctic, the market should increasingly value optionality on lifecycle expansion and geographic penetration rather than treating Leqembi as a binary launch story.

Second-order, the beneficiaries extend beyond the originator: infusion infrastructure, Alzheimer’s diagnostics, and real-world evidence vendors should see a longer runway if utilization keeps compounding. The competitive read-through is more subtle: a stronger sales bridge raises the bar for rival anti-amyloid programs by making market-share gains harder to win on efficacy alone, shifting competition toward convenience, safety monitoring burden, and payer economics. That favors operators with stronger commercial execution and reimbursement leverage, while leaving weaker entrants exposed to slower uptake and higher launch burn.

The main risk is that long-dated sales simulations can become self-reinforcing sentiment anchors that are vulnerable to any short-cycle disruption: safety findings, label tightening, reimbursement pushback, or slower-than-expected diagnosis conversion. Because the thesis unfolds over years, the stock can remain bid on expectation, but the first quarter of softer utilization or adverse-label noise would matter more than the FY28 endpoint. The contrarian view is that consensus may be underpricing execution drag: even if the demand pool is large, the bottleneck is often not physician belief but imaging capacity, infusion logistics, and patient persistence.

Net: this is constructive for the ecosystem, but the cleanest expression is likely in names with operating leverage to adoption rather than in the clinical story itself. If the market starts extrapolating FY28 sales too aggressively, that creates an opportunity to fade overowned optimism in the pure-play beneficiary and rotate into the picks-and-shovels layer.

Key Decisions for Investors

• Long BIOA B into pullbacks over the next 1-3 weeks, but size modestly: use the improved visibility to support a tactical re-rating trade, not a core hold. Risk/reward is attractive if the market prices a higher probability of FY28 commercial success, but trim if the stock runs ahead of actual prescription data.
• Pair trade: long infusion/diagnostics enablers vs. short a basket of Alzheimer’s late-stage competitors over 1-3 months. The thesis is that stronger Leqembi expectations widen the gap between commercial leaders and challengers whose economics worsen if adoption stays infrastructure-constrained.
• If options are liquid, buy medium-dated calls on BIOA B or the closest listed exposure for a 3-6 month horizon. Use defined risk because the catalyst is sentiment/visibility rather than an imminent fundamental step-up, and implied volatility may be cheaper than the optionality of a broadened adoption curve.
• Set a downside alert around any reimbursement or safety headline in the next 30-90 days; that is the highest-probability reversal mechanism. If such a headline lands, fade the move rather than averaging down, because the market will quickly reassess the long-dated sales path.
• Consider accumulating names tied to Alzheimer’s diagnostic throughput and infusion capacity on weakness over the next quarter. These are the cleaner second-order beneficiaries if the market continues to believe the FY28 sales simulation and the real bottleneck becomes operational scaling.